[Clinical Efficacy of Radiotherapy Combined with Chemotherapy for Primary Mediastinal Large B-cell Lymphoma]

To explore the clinical efficacy of radiotherapy combined with chemotherapy for patients with primary mediastinal large B-cell lymphoma(PMLBCL).

A total of 34 cases of PMLBCL were treated by radiotherapy combined with chemotherapy(radio-chemotherapy group), 28 cases of PMLBCL were treated by chemotherapy alone (single chemotherapy group as control). The clinical efficacy, side effects, long-term survival of the two group patients were compared.

The overall remission(OR) in the radio-chemotherapy group were higher than that in single chemotherapy group (P<0.05); the blood toxicity reaction, mucositis, radiation dermatitis in radio-chemotherapy group were higher than those in single chemotherapy group (P<0.05); the progress free survival(PFS) for 1 year in radio-chemotherapy group was higher than that in the single chemotherapy group (P<0.05), the local control (LC), PFS for 3 years in the radio-chemotherapy group were higher than those in the single chemotherapy group (P<0.05), the LC, OS, PFS for 5 years in the radio-chemotherapy group were higher than those in the single chemotherapy group (P<0.05).

The radiotherapy combined with chemotherapy has good clinical efficacy for patients with primary mediastinal large B-cell lymphoma, it has high rate of progression-free survival, it can be used as optimed scheme for treating PMLBCL, but the complications resulting from radio-chemotherapy should be prevented.